Amgen (AMGN) has been consistently
outperforming the stock market, with its shares rising by 5.8% since the last earnings report. The company reported strong financial results for the first, second and third quarters of 2024. Their performance is attributed to the promising reviews and attraction from investors for its
innovative solutions, particularly in obesity treatment. The company made major strides with its weight-loss drug, leading to a surge in the stock market. The FDA approved its drug
Blincyto for cancer treatment and
Uplizna for a rare disease. The FDA also granted priority review to
Tarlatamab for advanced small cell lung cancer. However, the company's stock fell in the Q2 earnings and it lowered its guidance. Despite these challenges,
analysts believe in Amgen's long-term growth prospects. The company's strategic approach towards the obesity drug market has been recognized, and their performance boosted by 'encouraging' obesity drug updates.
Amgen AMGN News Analytics from Tue, 12 Dec 2023 08:00:00 GMT to Tue, 10 Sep 2024 21:50:19 GMT -
Rating 6
- Innovation 7
- Information 8
- Rumor -2
